H

    Humacyte Inc (HUMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.60
    -0.05 (-7.49%)

    Market Cap: $167.07M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(11/22)
    Avg Surprise
    +15.83%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.10 - $-0.06
    3 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.11-32.1%
    60d ago$-0.11-29.1%
    30d ago$-0.09-8.0%
    7d ago$-0.09-8.0%
    Current$-0.08
    Revenue Consensus
    $2M
    Range$1M - $3M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.16 - $-0.04
    4 analysts
    Revenue Consensus
    $-1241900
    Range$-2653700 - $439300
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.08---
    Jun 26
    Reported Aug 10
    		$-0.16$-0.10-60.00%Miss+33.3%
    Mar 26
    Reported May 13
    		$-0.09$-0.11+18.18%Beat-132.1%
    Dec 25
    Reported Mar 27
    		$-0.19$-0.13-46.42%Miss+10.1%
    Sep 25
    Reported Nov 12
    		$-0.11$-0.15+26.67%Beat+57.7%
    Jun 25
    Reported Aug 11
    		$-0.24$-0.18-33.33%Miss+50.0%
    Mar 25
    Reported May 13
    		$0.28$-0.21+233.33%Beat+212.0%
    Dec 24
    Reported Mar 28
    		$-0.21$-0.26+18.00%Beat+12.9%
    Sep 24
    Reported Nov 8
    		$-0.26$-0.24-8.33%Miss-8.3%
    Jun 24
    Reported Aug 13
    		$-0.48$-0.24-100.00%Miss-166.7%
    Mar 24
    Reported May 10
    		$-0.25$-0.23-8.70%Miss-13.6%
    Dec 23
    Reported Mar 22
    		$-0.24$-0.24+0.00%Beat-500.0%
    Sep 23
    Reported Nov 9
    		$-0.24$-0.25+4.00%Beat+0.0%
    Jun 23
    Reported Aug 14
    		$-0.18$-0.22+18.18%Beat+5.3%
    Mar 23
    Reported May 12
    		$-0.22$-0.21-4.76%Miss+0.0%
    Dec 22
    Reported Mar 24
    		$-0.04N/A+82.61%Beat-109.8%
    Sep 22
    Reported Nov 10
    		$-0.24$-0.22-9.09%Miss+52.0%
    Jun 22
    Reported Aug 12
    		$-0.19$-0.22+13.64%Beat+75.0%
    Mar 22
    Reported May 13
    		$-0.22$-0.21-4.76%Miss-10.0%
    Dec 21
    Reported Mar 29
    		$0.41$-0.20+305.00%Beat+4200.0%
    Sep 21
    Reported Nov 12
    		$-0.50$-0.21-138.10%Miss-
    Jun 21
    Reported Aug 16
    		$-0.76$-0.56-35.71%Miss-
    Mar 21
    Reported May 17
    		$-0.20N/A+77.78%Beat-
    Dec 20
    Reported Feb 16
    		$-0.01N/AN/ABeat-
    Sep 20
    Reported Nov 12
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.10EV/EBITDA4.34x
    Price/FCF-1.44xFCF Yield-69.27%
    Profitability
    Profit Margin0.00%Operating Margin-6649.00%
    ROE-548.00%ROIC-77.13%
    Financial Health
    Debt/Equity1.16xInterest Coverage-2.03x
    Current Ratio6.21xQuick Ratio5.74x
    Trading Statistics
    Beta2.47Avg Volume9.21M
    52-Week High$2.5552-Week Low$0.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.66
    SMA 20$0.67
    SMA 50$0.68
    SMA 200$0.95
    EMA 10$0.66
    EMA 20$0.66
    EMA 50$0.72
    EMA 200$1.04

    MACD

    Line: -0.02Signal: -0.02Hist: 0.00

    ADX

    ADX: 14.5+DI: 18.6-DI: 25.9

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down56.0
    PSAR$0.56

    Bollinger Bands

    Upper Band$0.78
    Lower Band$0.55
    %B Position3547%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    43.0

    Momentum Oscillators

    Stoch %K54.5
    Stoch %D65.0
    Williams %R-66.4
    ROC (10d)7.3%
    Momentum0.04
    CCI (20d)-84.1
    MFI (14d)21.8

    Volatility Measures

    ATR (14d)$0.06(10.8%)
    StdDev (20d)0.06
    Hist Vol140.7%(High)

    Volume Flow

    VWAP$0.61
    OBV-336.8M
    AD Line-304.6M
    CMF (20d)-0.017

    Volume Metrics

    Avg Vol (20d)9.5M
    Vol Ratio1.4x
    VWMA (20d)$0.63

    Pivot Points

    R3$0.74
    R2$0.72
    R1$0.68
    Pivot Point$0.66
    S1$0.63
    S2$0.61
    S3$0.57

    Advanced Oscillators

    TSI-5.68
    Ultimate Osc37.9
    KST-36.19

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$406,000$495,000$467,000$753,000$301,000$517,000$7.23M$0$0$0$10.79M$0
    Cost of Revenue$1.23M$2.04M$8.78M$260,000$413,000$247,000$3.61M$0$0$0$3.38M$0
    Gross Profit$-825,000$-1,543,000$-8,315,000$493,000$-112,000$270,000$3.61M$0$0$0$-3,378,000$0
    Operating Expenses$26.17M$27.39M$22.22M$24.88M$29.82M$23.55M$28.09M$30.23M$29.50M$26.58M$26.18M$24.62M
    R&D$18.14M$19.46M$14.61M$17.27M$22.01M$15.42M$20.66M$22.93M$23.75M$21.26M$20.18M$18.55M
    SG&A$8.03M$7.93M$7.62M$7.61M$7.81M$8.14M$7.43M$7.31M$5.75M$5.31M$6.00M$6.07M
    Operating Income$-26,996,000$-28,935,000$-30,836,000$-24,390,000$-29,727,000$-23,184,000$-28,088,000$-30,233,000$-29,499,000$-26,578,000$-26,182,000$-24,622,000
    Interest Income$388,000$330,000$503,000$590,000$832,000$662,000$852,000$911,000$1.31M$1.03M$1.14M$1.37M
    Interest Expense$2.32M$2.27M$25.36M$2.61M$2.54M$3.00M$2.51M$2.44M$2.52M$1.82M$1.73M$1.46M
    Income Before Tax$-36,802,000$-17,619,000$-24,804,000$-17,510,000$-37,658,000$39.14M$-20,940,000$-39,202,000$-56,663,000$-31,896,000$-25,106,000$-25,995,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-36,802,000$-17,619,000$-24,804,000$-17,510,000$-37,658,000$39.14M$-20,940,000$-39,202,000$-56,663,000$-31,896,000$-25,106,000$-25,995,000
    EBITDA$-32,785,000$-13,606,000$1.84M$-13,623,000$-34,085,000$43.31M$-17,476,000$-35,863,000$-53,679,000$-29,320,000$-22,690,000$-24,071,000
    EBIT$-34,869,000$-15,678,000$53,000$-15,488,000$-35,945,000$41.48M$-19,284,000$-37,675,000$-55,458,000$-31,111,000$-24,523,000$-25,901,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HUMA

    News

    Humacyte (NASDAQ: HUMA) pulls redeemable warrants from Nasdaq

    Humacyte, Inc. (HUMA) has voluntarily withdrawn its redeemable warrants from listing and registration on the Nasdaq Stock Market LLC. Each warrant was exercisable for one share of common stock at an exercise price of $11.50. The removal was executed under Section 12(b) of the Securities Exchange Act of 1934 and relevant CFR rules, with Nasdaq certifying compliance for the Form 25 filing.

    Stock Titan•8/25/26•
    Somewhat-Bearish

    Humacyte Plans November 2026 Supplemental BLA Submission for ATEV Dialysis Access Based on Phase 3 Data

    Humacyte plans to submit a supplemental Biologics License Application (BLA) for its acellular tissue engineered vessel (ATEV) for dialysis access by November 2026. This submission follows positive Phase 3 study results, including the V012 study which showed ATEV provided women with three additional months without a dialysis catheter compared to the standard AV fistula. The company is confident in its regulatory path after discussions with the FDA, aiming to address unmet needs for dialysis patients.

    Quiver Quantitative•8/24/26•
    Bullish

    Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

    Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and its stock price due to the strong correlation between earnings estimate revisions and near-term stock movements. The Zacks Rank system, which categorizes stocks based on earnings estimate revisions, indicates that HUMA is now in the top 20% of Zacks-covered stocks, making it a strong candidate for market-beating returns.

    Eastern Progress•8/22/26•
    Bullish

    Investigation into Humacyte continues after FDA cites manufacturing violations and lawsuit proceeds.

    Kahn Swick & Foti, LLC is investigating Humacyte, Inc. following an FDA inspection that found significant manufacturing violations, including issues with microbial quality assurance and testing. This led to a delay in the FDA's approval of Humacyte's Biologic License Application. Additionally, a securities class action lawsuit against the company is moving forward, alleging that Humacyte and its executives failed to disclose material information to investors.

    Pluang•8/22/26•
    Bearish

    Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

    Kahn Swick & Foti, LLC (KSF) is continuing its investigation into Humacyte, Inc. (HUMA) and its officers and directors following a securities class action lawsuit. The lawsuit stems from Humacyte's announcement in August 2024 that the FDA required more time to review its Biologic License Application and a subsequent FDA Form 483 in October 2024 detailing manufacturing violations. KSF's investigation focuses on potential breaches of fiduciary duties or violations of state or federal laws by Humacyte's leadership.

    Morningstar•8/22/26•
    Bearish

    Frequently Asked Questions About HUMA

    Does HUMA pay dividends?
    Humacyte Inc (HUMA) does not currently pay a regular dividend.
    What is HUMA's market cap?
    Humacyte Inc (HUMA) has a market capitalization of $167.07M with a current stock price of $0.60.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In